orforglipron glp 1 In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes WIKIMOLE—Orforglipron
Pay in 4 interest-free payments of $5.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24



























